Skip to NavigationSkip to content

News

0
After a 20-hour debate, Greek parliament has voted in favour of investigating 10 politicians named as part of an investigation into alleged bribery...
0
A year to the day that the FDA unveiled its Final Rule, which sees organisation given 13 months from clinical trial completion to publish summary...
0
NICE has published its decision not to recommend Eisai’s Halaven (eribulin) in the treatment of locally advanced or metastatic breast cancer after...
0
The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for the coming flu seasons.

Features

Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the migraine space to...